$15 Million for Calimmune and California Stem Cell HIV Trial
By David Jensen,
California Stem Cell Report
| 05. 27. 2015
Untitled Document
Calimmune, Inc., which has received $8.3 million from the California stem cell agency, today announced it has rustled up another $15 million to help out with the work that the agency is backing.
Calimmune of Tucson, Ariz., was co-founded by a former agency board member and Nobel Prize winner David Baltimore. It is currently engaged in a clinical trial in Los Angeles and San Francisco involving a treatment for HIV.
“Calimmune hasn't had much of a profile outside of the HIV world, but (CEO Louis) Breton is looking to change that. The company has a staff of 40 now, he says, and is looking to expand and possibly strike a partnership deal with a Big Pharma in the space. And unlike some of the leading gene therapy companies in the industry which are targeting tiny populations, Calimmune is tackling a treatment for a disease with a huge, global population of patients. Discussions about million-dollar therapies, he says, won't work for something like HIV.
"‘Our mission,’ says Breton...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Teddy Rosenbluth, The New York Times | 02.09.2026
Dr. Mehmet Oz has urged Americans to get vaccinated against measles, one of the strongest endorsements of the vaccine yet from a top health official in the Trump administration, which has repeatedly undermined confidence in vaccine safety.
Dr. Oz, the...
By Alex Polyakov, The Conversation | 02.09.2026
Prospective parents are being marketed genetic tests that claim to predict which IVF embryo will grow into the tallest, smartest or healthiest child.
But these tests cannot deliver what they promise. The benefits are likely minimal, while the risks to...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...